Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Preoperative respiratory muscle endurance training improves ventilatory capacity and prevents pulmonary postoperative complications after lung surgery: a randomized controlled trial.

Laurent H, Aubreton S, Galvaing G, Pereira B, Merle P, Richard R, Costes F, Filaire M.

Eur J Phys Rehabil Med. 2019 Sep 4. doi: 10.23736/S1973-9087.19.05781-2. [Epub ahead of print]

2.

Statin-associated myasthenia: A case report and literature review.

Gras-Champel V, Masmoudi I, Batteux B, Merle PE, Liabeuf S, Masmoudi K.

Therapie. 2019 Jul 26. pii: S0040-5957(19)30121-0. doi: 10.1016/j.therap.2019.07.004. [Epub ahead of print] No abstract available.

PMID:
31477339
3.

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).

Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM.

Oncoimmunology. 2019 Jun 3;8(8):1615817. doi: 10.1080/2162402X.2019.1615817. eCollection 2019.

4.

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Faivre S, Benhadji KA, Giannelli G.

Clin Transl Gastroenterol. 2019 Jul;10(7):e00056. doi: 10.14309/ctg.0000000000000056.

PMID:
31295152
5.

Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.

Bonnin M, Fares N, Testoni B, Estornes Y, Weber K, Vanbervliet B, Lefrançois L, Garcia A, Kfoury A, Pez F, Coste I, Saintigny P, Viari A, Lang K, Guey B, Hervieu V, Bancel B, Bartoch B, Durantel D, Renno T, Merle P, Lebecque S.

J Hepatol. 2019 Jun 18. pii: S0168-8278(19)30351-4. doi: 10.1016/j.jhep.2019.05.031. [Epub ahead of print]

PMID:
31220470
6.

Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.

Rimassa L, Danesi R, Pressiani T, Merle P.

Cancer Treat Rev. 2019 Jul;77:20-28. doi: 10.1016/j.ctrv.2019.05.004. Epub 2019 May 15. Review.

7.

Neoadjuvant conformal radiotherapy before liver transplantation for hepatocellular carcinoma: a propensity score matched analysis of postoperative morbidity and oncological results.

Mourad M, Mabrut JY, Chellakhi M, Lesurtel M, Prevost C, Ducerf C, Rode A, Merle P, Mornex F, Mohkam K.

Future Oncol. 2019 Jul;15(21):2517-2530. doi: 10.2217/fon-2019-0127. Epub 2019 Jun 10.

PMID:
31179766
8.

Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 T-type voltage-gated calcium channels and Ca2+ influx.

Jimenez H, Wang M, Zimmerman JW, Pennison MJ, Sharma S, Surratt T, Xu ZX, Brezovich I, Absher D, Myers RM, DeYoung B, Caudell DL, Chen D, Lo HW, Lin HK, Godwin DW, Olivier M, Ghanekar A, Chen K, Miller LD, Gong Y, Capstick M, D'Agostino RB Jr, Munden R, Merle P, Barbault A, Blackstock AW, Bonkovsky HL, Yang GY, Jin G, Liu L, Zhang W, Watabe K, Blackman CF, Pasche BC.

EBioMedicine. 2019 Jun;44:209-224. doi: 10.1016/j.ebiom.2019.05.034. Epub 2019 May 31.

9.

Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.

Wang H, Lekbaby B, Fares N, Augustin J, Attout T, Schnuriger A, Cassard AM, Panasyuk G, Perlemuter G, Bieche I, Vacher S, Selves J, Péron JM, Bancel B, Merle P, Kremsdorf D, Hall J, Chemin I, Soussan P.

Hepatol Int. 2019 Jul;13(4):454-467. doi: 10.1007/s12072-019-09950-7. Epub 2019 May 28.

PMID:
31140152
10.

Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.

Garcia J, Wozny AS, Geiguer F, Delherme A, Barthelemy D, Merle P, Tissot C, Jones FS, Johnson C, Xing X, Xu Z, Edelstein DL, Brevet M, Souquet PJ, Rodriguez-Lafrasse C, Payen L, Couraud S.

Cancer Med. 2019 Jul;8(8):3685-3697. doi: 10.1002/cam4.2244. Epub 2019 May 21.

11.

Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial.

Guiu B, Chevallier P, Assenat E, Barbier E, Merle P, Bouvier A, Dumortier J, Nguyen-Khac E, Gugenheim J, Rode A, Oberti F, Valette PJ, Yzet T, Chevallier O, Barbare JC, Latournerie M, Boulin M.

Radiology. 2019 Jun;291(3):801-808. doi: 10.1148/radiol.2019182399. Epub 2019 Apr 30.

PMID:
31038408
12.

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.

Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e6.

PMID:
30954567
13.

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.

Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V.

Br J Cancer. 2019 Apr;120(9):896-902. doi: 10.1038/s41416-019-0443-4. Epub 2019 Apr 4.

PMID:
30944458
14.

Comprehensive two-dimensional gas chromatography coupled with time of flight mass spectrometry featuring tandem ionization: Challenges and opportunities for accurate fingerprinting studies.

Cordero C, Guglielmetti A, Bicchi C, Liberto E, Baroux L, Merle P, Tao Q, Reichenbach SE.

J Chromatogr A. 2019 Jul 19;1597:132-141. doi: 10.1016/j.chroma.2019.03.025. Epub 2019 Mar 18.

PMID:
30922719
15.

Odorants quantitation in high-quality cocoa by multiple headspace solid phase micro-extraction: Adoption of FID-predicted response factors to extend method capabilities and information potential.

Cordero C, Guglielmetti A, Sgorbini B, Bicchi C, Allegrucci E, Gobino G, Baroux L, Merle P.

Anal Chim Acta. 2019 Apr 4;1052:190-201. doi: 10.1016/j.aca.2018.11.043. Epub 2018 Nov 24.

PMID:
30685038
16.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.

Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

PMID:
30665869
17.

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.

Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, Guisier F, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault A, Rabeau A, Antoine M, Denis MG, Bommart S, Langlais A, Morin F, Souquet PJ.

J Thorac Oncol. 2019 May;14(5):903-913. doi: 10.1016/j.jtho.2019.01.008. Epub 2019 Jan 18.

PMID:
30664989
18.

Evaluation of postoperative ascites after somatostatin infusion following hepatectomy for hepatocellular carcinoma by laparotomy: a multicenter randomized double-blind controlled trial (SOMAPROTECT).

Mohkam K, Rayar M, Adam JP, Muscari F, Rode A, Merle P, Pradat P, Bauler S, Delfour I, Chiche L, Ducerf C, Boudjema K, Lesurtel M, Laurent C, Mabrut JY.

BMC Cancer. 2018 Aug 23;18(1):844. doi: 10.1186/s12885-018-4667-0.

19.

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK.

N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.

20.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.

Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM.

Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. doi: 10.1158/1078-0432.CCR-17-3588. Epub 2018 Jun 27.

21.

Recommendations for the use of electroencephalography and evoked potentials in comatose patients.

André-Obadia N, Zyss J, Gavaret M, Lefaucheur JP, Azabou E, Boulogne S, Guérit JM, McGonigal A, Merle P, Mutschler V, Naccache L, Sabourdy C, Trébuchon A, Tyvaert L, Vercueil L, Rohaut B, Delval A.

Neurophysiol Clin. 2018 Jun;48(3):143-169. doi: 10.1016/j.neucli.2018.05.038. Epub 2018 May 18. Review.

PMID:
29784540
22.

Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy).

Garcia J, Forestier J, Dusserre E, Wozny AS, Geiguer F, Merle P, Tissot C, Ferraro-Peyret C, Jones FS, Edelstein DL, Cheynet V, Bardel C, Vilchez G, Xu Z, Bringuier PP, Barritault M, Brengle-Pesce K, Guillet M, Chauvenet M, Manship B, Brevet M, Rodriguez-Lafrasse C, Hervieu V, Couraud S, Walter T, Payen L.

Oncotarget. 2018 Apr 20;9(30):21122-21131. doi: 10.18632/oncotarget.24950. eCollection 2018 Apr 20.

23.

Hepatic venous pressure gradient after portal vein embolization: An accurate predictor of future liver remnant hypertrophy.

Mohkam K, Rode A, Darnis B, Manichon AF, Boussel L, Ducerf C, Merle P, Lesurtel M, Mabrut JY.

Surgery. 2018 Aug;164(2):227-232. doi: 10.1016/j.surg.2018.03.014. Epub 2018 May 10.

PMID:
29753461
24.

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.

Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J.

J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.

PMID:
29704513
25.

Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults.

Komas NP, Ghosh S, Abdou-Chekaraou M, Pradat P, Al Hawajri N, Manirakiza A, Laghoe GL, Bekondi C, Brichler S, Ouavéné JO, Sépou A, Yambiyo BM, Gody JC, Fikouma V, Gerber A, Abeywickrama Samarakoon N, Alfaiate D, Scholtès C, Martel N, Le Gal F, Lo Pinto H, Amri I, Hantz O, Durantel D, Lesbordes JL, Gordien E, Merle P, Drugan T, Trépo C, Zoulim F, Cortay JC, Kay AC, Dény P.

PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006377. doi: 10.1371/journal.pntd.0006377. eCollection 2018 Apr.

26.

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.

Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).

Eur Respir J. 2018 Mar 15;51(3). pii: 1701467. doi: 10.1183/13993003.01467-2017. Print 2018 Mar.

27.

Large hepatocellular carcinoma: Does fibrosis really impact prognosis after resection?

Golse N, El Bouyousfi A, Marques F, Bancel B, Mohkam K, Ducerf C, Merle P, Sebagh M, Castaing D, Sa Cunha A, Adam R, Cherqui D, Vibert E, Mabrut JY.

J Visc Surg. 2018 Sep;155(4):265-273. doi: 10.1016/j.jviscsurg.2017.10.015. Epub 2018 Mar 7.

PMID:
29525540
28.

No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm.

Mohkam K, Dumont PN, Manichon AF, Jouvet JC, Boussel L, Merle P, Ducerf C, Lesurtel M, Rode A, Mabrut JY.

J Hepatol. 2018 Jun;68(6):1172-1180. doi: 10.1016/j.jhep.2018.01.014. Epub 2018 Feb 2.

PMID:
29410287
29.

Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma.

Merle P, Camus P, Abergel A, Pageaux GP, Masliah C, Bronowicki JP, Zarski JP, Pelletier G, Bouattour M, Farloux L, Dorval E, Verset G, Si-Ahmed SN, Doffoel M, Couzigou P, Taieb J, Vasseur B, Attali P.

ESMO Open. 2017 Oct 23;2(4):e000238. doi: 10.1136/esmoopen-2017-000238. eCollection 2017.

30.

Down-regulation of the Wnt/β-catenin signaling pathway by Cacnb4.

Rima M, Daghsni M, Lopez A, Fajloun Z, Lefrancois L, Dunach M, Mori Y, Merle P, Brusés JL, De Waard M, Ronjat M.

Mol Biol Cell. 2017 Dec 1;28(25):3699-3708. doi: 10.1091/mbc.E17-01-0076. Epub 2017 Oct 11.

31.

Asleep Robot-Assisted Surgery for the Implantation of Subthalamic Electrodes Provides the Same Clinical Improvement and Therapeutic Window as Awake Surgery.

Lefranc M, Zouitina Y, Tir M, Merle P, Ouendo M, Constans JM, Godefroy O, Peltier J, Krystkowiak P.

World Neurosurg. 2017 Oct;106:602-608. doi: 10.1016/j.wneu.2017.07.047. Epub 2017 Jul 19.

PMID:
28735132
32.

Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.

Williet N, Clavel L, Bourmaud A, Verot C, Bouarioua N, Roblin X, Merle P, Phelip JM.

Dig Liver Dis. 2017 Sep;49(9):1043-1049. doi: 10.1016/j.dld.2017.06.008. Epub 2017 Jun 23.

PMID:
28712860
33.

Cardiac Abnormalities in Type 1 Facioscapulohumeral Muscular Dystrophy.

Labombarda F, Maurice M, Simon JP, Legallois D, Guyant-Maréchal L, Bedat-Millet AL, Merle P, Saloux E, Chapon F, Milliez P.

J Clin Neuromuscul Dis. 2017 Jun;18(4):199-206. doi: 10.1097/CND.0000000000000144.

PMID:
28538250
34.

Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.

Virlogeux V, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, Ouziel G, Poinsot D, Lebossé F, Ecochard M, Radenne S, Benmakhlouf S, Koffi J, Lack P, Scholtes C, Uhres AC, Ducerf C, Mabrut JY, Rode A, Levrero M, Combet C, Merle P, Zoulim F.

Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.

PMID:
28423231
35.

Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma.

Holmila R, Sklias A, Muller DC, Degli Esposti D, Guilloreau P, Mckay J, Sangrajrang S, Srivatanakul P, Hainaut P, Merle P, Herceg Z, Nogueira da Costa A.

PLoS One. 2017 Mar 23;12(3):e0174265. doi: 10.1371/journal.pone.0174265. eCollection 2017.

36.

mRECIST for systemic therapies: More evidence is required before recommendations can be made.

Edeline J, Palmer D, Blanc JF, Campillo-Gimenez B, Merle P, Meyer T.

J Hepatol. 2017 Jul;67(1):195. doi: 10.1016/j.jhep.2017.02.033. Epub 2017 Mar 16. No abstract available.

PMID:
28315710
37.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators.

Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Erratum in: Lancet. 2017 Jan 7;389(10064):36.

PMID:
27932229
38.

Characterization of glutathione peroxidase diversity in the symbiotic sea anemone Anemonia viridis.

Pey A, Zamoum T, Christen R, Merle PL, Furla P.

Biochimie. 2017 Jan;132:94-101. doi: 10.1016/j.biochi.2016.10.016. Epub 2016 Nov 8.

PMID:
27833038
39.

DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection.

Fan H, Cui Z, Zhang H, Mani SK, Diab A, Lefrancois L, Fares N, Merle P, Andrisani O.

Oncogene. 2017 Apr 27;36(17):2435-2445. doi: 10.1038/onc.2016.399. Epub 2016 Oct 31.

40.

EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes.

Mani SK, Zhang H, Diab A, Pascuzzi PE, Lefrançois L, Fares N, Bancel B, Merle P, Andrisani O.

J Hepatol. 2016 Nov;65(5):888-898. doi: 10.1016/j.jhep.2016.05.022. Epub 2016 May 26.

41.

Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC.

Hocquelet A, Aubé C, Rode A, Cartier V, Sutter O, Manichon AF, Boursier J, N'kontchou G, Merle P, Blanc JF, Trillaud H, Seror O.

J Hepatol. 2017 Jan;66(1):67-74. doi: 10.1016/j.jhep.2016.07.010. Epub 2016 Jul 13.

PMID:
27422750
42.

RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis.

Zhang H, Xing Z, Mani SK, Bancel B, Durantel D, Zoulim F, Tran EJ, Merle P, Andrisani O.

Hepatology. 2016 Oct;64(4):1033-48. doi: 10.1002/hep.28698. Epub 2016 Aug 8.

43.

Neurofascin-155 as a putative antigen in combined central and peripheral demyelination.

Cortese A, Devaux JJ, Zardini E, Manso C, Taieb G, Carra Dallière C, Merle P, Osera C, Romagnolo S, Visigalli N, Piscosquito G, Salsano E, Alfonsi E, Moglia A, Pareyson D, Marchioni E, Franciotta D.

Neurol Neuroimmunol Neuroinflamm. 2016 Jun 7;3(4):e238. doi: 10.1212/NXI.0000000000000238. eCollection 2016 Aug. No abstract available.

44.

Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review.

Golse N, Radenne S, Rode A, Ducerf C, Mabrut JY, Merle P.

Exp Clin Transplant. 2018 Apr;16(2):227-236. doi: 10.6002/ect.2015.0299. Epub 2016 May 17. Review.

45.

Conformal radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma: is it safe?

Mohkam K, Golse N, Bonal M, Ledochowski S, Rode A, Selmaji IE, Merle P, Ducerf C, Mornex F, Mabrut JY.

Future Oncol. 2016 Jul;12(13):1577-86. doi: 10.2217/fon-2016-0083. Epub 2016 Apr 20.

PMID:
27095680
46.

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Ukrainskyj S, Boisserie F, Rutman O, Chen YC, Xu C, Shochat E, Jukofsky L, Reis B, Chen G, Di Laurenzio L, Lee R, Yen CJ.

J Hepatol. 2016 Aug;65(2):289-95. doi: 10.1016/j.jhep.2016.04.004. Epub 2016 Apr 13.

PMID:
27085251
47.

Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing.

Esposti DD, Hernandez-Vargas H, Voegele C, Fernandez-Jimenez N, Forey N, Bancel B, Le Calvez-Kelm F, McKay J, Merle P, Herceg Z.

Oncotarget. 2016 May 31;7(22):31862-77. doi: 10.18632/oncotarget.7364.

48.

Extended resection of non-small cell lung cancer invading the left atrium, is it worth the risk?

Galvaing G, Chadeyras JB, Merle P, Tardy MM, Naamee A, Bailly P, Filaire M.

Chin Clin Oncol. 2015 Dec;4(4):43. doi: 10.3978/j.issn.2304-3865.2015.06.08. Review.

49.

Prophylactic tracheotomy and lung cancer resection in patient with low predictive pulmonary function: a randomized clinical trials.

Filaire M, Tardy MM, Richard R, Naamee A, Chadeyras JB, Da Costa V, Bailly P, Eisenmann N, Pereira B, Merle P, Galvaing G.

Chin Clin Oncol. 2015 Dec;4(4):40. doi: 10.3978/j.issn.2304-3865.2015.11.05.

50.

Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.

Jeannin G, Merle P, Janicot H, Thibonnier L, Kwiatkowski F, Naame A, Chadeyras JB, Galvaing G, Belliere A, Filaire M, Verrelle P.

Chin Clin Oncol. 2015 Dec;4(4):39. doi: 10.3978/j.issn.2304-3865.2015.12.01.

Supplemental Content

Support Center